develop
commerci
multiplex
panel
detect
diagnosi
lower
respiratori
tract
infect
rapidli
progress
fdaclear
assay
current
avail
review
provid
comprehens
overview
current
soontob
avail
commerci
assay
focus
analyt
perform
advantag
challeng
potenti
impact
patient
outcom
laboratori
deploy
assay
cmn
clinic
microbiolog
newslett
aid
detect
variou
infect
use
multiplex
molecular
panel
syndrom
test
ie
test
specimen
multipl
pathogen
common
bodi
site
becom
commonplac
laboratori
avail
panel
detect
pathogen
blood
stool
upper
respiratori
tract
specimen
aim
provid
rapid
identif
bacteria
virus
instanc
provid
preliminari
antimicrobi
resist
test
limit
number
antibiot
incorpor
widespread
use
variou
respiratori
viral
panel
rvp
nasopharyng
swab
revolution
upper
respiratori
tract
infect
diagnos
manag
use
rvp
led
rapid
result
improv
use
antivir
treatment
better
hospit
infect
control
practic
rvp
implement
mani
laboratori
receiv
rvp
request
test
lower
respiratori
tract
lrt
specimen
bronchoalveolar
lavag
bal
fluid
aid
diagnosi
viral
pneumonia
reveal
diagnost
gap
syndrom
test
avail
time
respons
diagnost
compani
develop
new
molecular
multiplex
panel
diagnosi
pneumonia
panel
primarili
focu
improv
detect
bacteri
pathogen
bal
fluid
sputum
endotrach
aspir
tradit
cultur
gold
standard
detect
diagnosi
pneumonia
howev
cultur
sensit
method
even
perform
highqual
sampl
given
enhanc
sensit
molecular
method
use
multiplex
lower
respiratori
panel
lrp
could
significantli
improv
upon
current
cultur
techniqu
review
present
current
upcom
commerci
assay
discuss
practic
matter
laboratori
consid
deploy
test
lrp
recent
interest
use
molecular
method
diagnosi
lrt
infect
led
develop
multiplex
laboratorydevelop
test
ldt
ldt
method
target
vari
wide
worth
briefli
discuss
noncommerci
altern
develop
ldt
use
tradit
realtim
multiplex
pcr
assay
somewhat
limit
scope
compar
commerci
assay
number
target
one
reliabl
detect
approxim
assay
perform
significantli
suffer
approach
consist
vol
august
wwwcmnewslettercom
detect
viral
pathogen
specif
upper
respiratori
tract
specimen
limit
develop
ldt
detect
bacteri
pathogen
lrt
semiquantit
multiplex
ldt
detect
bacteri
pathogen
lrt
sampl
develop
aid
diagnosi
communityacquir
pneumonia
use
combin
multiplex
target
tabl
gadsbi
et
al
develop
ldt
panel
detect
mani
pathogen
sputum
endotrach
aspir
semiquantif
subset
bacteri
target
achiev
use
standard
curv
gener
serial
dilut
plasmid
contain
gene
target
use
backcalcul
bacteri
densiti
term
cfu
per
millilit
cutoff
valu
appli
pathogen
densiti
cfuml
consid
clinic
signific
use
cutoff
sampl
posit
respiratori
pathogen
posit
bacteri
pathogen
high
concord
bacteri
pcr
standard
cultur
haemophilu
influenza
miss
pcr
two
sampl
addit
sampl
grew
bacteria
includ
pcr
panel
implement
rvp
upper
respiratori
tract
sampl
stimul
offlabel
use
panel
lrt
sampl
requir
assay
valid
lrt
specimen
ruggiero
colleagu
compar
perform
biofir
salt
lake
citi
ut
filmarray
fa
genmark
esensor
rvp
carlsbad
ca
retrospect
spike
lrt
specimen
retrospect
sampl
posit
via
viral
cultur
via
fa
via
esensor
fa
detect
two
coinfect
esensor
detect
four
anoth
studi
esensor
quidel
san
diego
ca
lyra
panther
san
diego
ca
fusion
compar
use
lrt
specimen
posit
result
two
three
assay
consid
true
posit
fusion
esensor
posit
agreement
target
test
influenza
viru
influenza
b
viru
respiratori
syncyti
viru
parainfluenza
viru
type
human
metapneumoviru
adenoviru
rhinoviru
lyra
variabl
posit
agreement
rang
neg
agreement
rang
fusion
esensor
lyra
respect
studi
includ
lrt
sampl
larger
evalu
commerci
approv
viral
panel
note
similar
perform
regardless
specimen
type
fa
pneumonia
panel
fapp
biofir
diagnost
salt
lake
citi
ut
recent
clear
us
food
drug
administr
fda
use
detect
lrt
infect
fapp
use
nest
multiplex
pcr
detect
common
bacteri
viral
respiratori
pathogen
also
includ
select
genet
antibiot
resist
marker
meca
carbapenemas
tabl
assay
test
sputumlik
sputum
endotrach
aspir
bal
fluidlik
bal
fluid
bronchoalveolar
wash
sampl
uniqu
assay
abil
provid
semiquantit
result
albeit
quantif
subset
bacteri
target
tabl
concept
behind
semiquantit
result
mimic
current
laboratori
practic
use
semiquantit
cultur
semiquantit
allow
interpret
rel
densiti
specif
bacteria
aid
clinic
interpret
molecular
result
semiquantit
function
achiev
util
bin
algorithm
base
rel
amount
quantit
target
pcr
amplicon
compar
known
concentr
intern
standard
limit
quantif
rang
copiesml
valu
copiesml
consid
neg
result
neg
result
similar
tradit
quantit
bal
fluid
cultur
coloni
cfuml
consid
clinic
signific
bin
algorithm
repres
densiti
rang
log
unit
upper
lower
limit
ie
bin
addit
resist
marker
report
bacteri
speci
harbor
resist
gene
present
densiti
cutoff
ie
sampl
pseudomona
aeruginosa
posit
would
report
meca
resist
time
write
studi
evalu
perform
fa
initi
studi
show
sensit
target
panel
sputum
bal
notabl
except
sensit
enterobact
aerogen
bal
fluid
sputum
respect
viral
target
adenoviru
low
sensit
sputum
coronaviru
sensit
bal
fluid
sputum
respect
addit
common
extendedspectrum
recov
clinic
laboratori
ctxm
low
sensit
sampl
type
note
target
could
assess
posit
sampl
includ
target
includ
acinetobact
speci
moraxella
catarrhali
bal
sampl
sampl
posit
middl
east
respiratori
syndrom
coronaviru
chlamydia
pneumonia
resist
marker
imp
one
sampl
posit
target
test
fa
detect
new
delhi
metallobetalactamas
ndm
bal
sampl
miss
legionella
pneumophila
sputum
target
specif
except
mecamecc
mrej
resist
marker
sputum
separ
studi
found
similar
perform
rate
bacteri
target
compar
standard
care
cultur
pcr
method
overal
percent
posit
agreement
ppa
bal
fluid
sputum
neg
percent
agreement
bal
fluid
sputum
viral
target
evalu
limit
antibiot
marker
assess
studi
interestingli
target
p
aeruginosa
staphylococcu
aureu
lower
averag
ppa
bal
fluid
sputum
respect
problemat
target
observ
studi
kerr
faron
addit
falseposit
result
observ
fa
major
patient
none
receiv
antibiot
therapi
hour
sampl
collect
like
explain
neg
cultur
result
cureti
unyvero
cureti
gmbh
system
clear
earlier
year
lrt
panel
test
endotrach
aspir
unyvero
system
consist
lysat
instrument
prep
sampl
analyz
test
cartridg
cockpit
system
control
process
interfac
laboratori
inform
system
li
clear
lrt
panel
contain
bacteri
target
marker
resist
tabl
importantli
system
provid
type
quantit
inform
simpli
report
presenc
absenc
target
date
extens
studi
multicent
clinic
trial
studi
test
prospect
tracheal
aspir
sampl
studi
sampl
posit
pathogen
overal
weight
sensit
organ
identif
compar
cultur
rang
posit
agreement
exclud
organ
fewer
identif
sampl
set
rang
posit
agreement
weight
specif
rang
neg
agreement
importantli
posit
lrt
detect
confirm
via
target
pcr
follow
bidirect
sequenc
determin
resist
marker
lrt
overal
weight
sensit
rang
posit
agreement
rang
overal
weight
specif
neg
percent
agreement
rang
contriv
sampl
util
augment
lowfrequ
target
rang
posit
agreement
collin
report
result
singlecent
studi
examin
perform
lrt
bal
sampl
posit
agreement
cultur
rang
neg
agreement
one
main
advantag
fdaapprov
panel
lrt
sampl
elimin
barrier
perform
lrt
molecular
diagnost
outsid
larger
hospit
laboratori
remov
develop
valid
regulatori
requir
ldt
offlabel
use
upper
respiratori
tract
panel
fda
approv
lrt
panel
allow
better
diagnosi
treatment
local
commun
hospit
set
goal
diagnost
test
provid
inform
direct
impact
patient
care
molecular
revolut
microbiolog
signific
impact
allow
quicker
identif
potenti
pathogen
result
downstream
benefit
improv
antibiot
util
one
small
retrospect
studi
conduct
assess
potenti
impact
fapp
antimicrobi
modif
prescrib
versu
standard
care
cultur
pcr
method
studi
found
patient
use
assay
could
result
appropri
antibiot
deescal
signific
reduct
time
deescal
use
fapp
guid
antibiot
therapi
estim
minim
risk
inappropri
modif
note
studi
also
found
patient
potenti
chang
therapi
fapp
use
singlecent
studi
perform
beaumont
hospit
michigan
report
theoret
impact
lrt
panel
manag
patient
suspect
pneumonia
studi
util
inform
panel
submit
fda
includ
target
ultim
approv
infecti
diseas
physician
evalu
patient
chart
appropri
antibiot
therapi
concern
final
cultur
organ
time
lrt
result
would
avail
patient
appropri
antibiot
time
lrt
result
would
avail
overtr
undertr
seventysix
percent
undertr
cohort
modifi
base
lrt
result
assess
perform
ldt
pneumonia
gadsbi
colleagu
also
retrospect
assess
potenti
impact
ldt
antimicrobi
prescrib
upon
review
studi
subject
antimicrobi
hour
lrt
sampl
obtain
inde
ldt
abl
detect
bacteria
pretreat
patient
cultur
posit
fapp
biggest
impact
ldt
potenti
appropri
deescal
antimicrobi
patient
smaller
impact
potenti
escal
potenti
chang
addit
comprehens
studi
need
preliminari
studi
strongli
suggest
benefit
use
lrp
either
commerci
assay
ldt
improv
antibiot
stewardship
improv
patient
outcom
clear
advantag
implement
lrp
challeng
address
laboratori
adopt
test
similar
multiplex
panel
lrp
includ
larg
number
target
rais
concern
variabl
sensit
target
may
unaccept
variabl
detect
appear
present
viral
antibiot
resist
target
fapp
may
discourag
laboratori
implement
panel
import
awar
sensit
issu
determin
util
panel
certain
patient
popul
interpret
neg
result
obtain
reliabl
neg
predict
valu
furthermor
breadth
panel
result
inclus
target
clinic
distinct
often
appli
specif
patient
popul
inclus
hospitalacquir
communityacquir
pathogen
present
challeng
decid
patient
test
perform
tradit
cultur
endotrach
aspir
sputum
sampl
laboratori
includ
accept
specimen
criteria
determin
specimen
appropri
cultur
sputum
calcul
white
blood
cellsquam
epitheli
cell
ratio
perform
via
gram
stain
ensur
sputum
saliva
repres
lrt
specimen
endotrach
aspir
undergo
similar
qualiti
check
via
gram
stain
presenc
absenc
bacteria
context
white
blood
cell
quantiti
use
intern
control
includ
panel
serv
specimen
qualiti
assess
target
white
blood
cell
squamou
cell
includ
ommiss
qualiti
assess
may
result
test
specimen
inferior
qualiti
inappropri
sampl
laboratori
strongli
consid
continu
use
gram
stain
assess
specimen
qualiti
prior
run
molecular
panel
anoth
challeng
interpret
posit
result
absenc
assess
normal
flora
advantag
tradit
cultur
unbias
natur
commens
pathogen
recov
interpret
pathogen
signific
lrt
specimen
often
guid
presenc
absenc
normal
flora
amount
compar
pathogen
question
especi
true
organ
colon
opportunist
pathogen
streptococcu
pneumonia
catarrhali
h
influenza
determin
organ
true
pathogen
often
challeng
particularli
pediatr
patient
colon
rate
higher
adult
place
densiti
potenti
pathogen
context
densiti
normal
flora
help
clinician
attempt
identifi
caus
pneumonia
semiquantit
bacteri
result
aim
address
concern
assay
still
lack
abil
definit
interpret
organ
colon
issu
also
potenti
problem
patient
chronic
tracheostomi
time
tracheostomi
tube
becom
colon
commonli
gramneg
bacteria
condit
current
challeng
proper
interpret
tradit
endotrach
aspir
cultur
could
even
confound
use
lrp
commerci
assay
includ
resist
marker
specimen
still
need
cultur
order
perfrom
antimicrobi
suscept
test
limit
studi
suggest
potenti
impact
lrp
panel
deescal
antibiot
studi
document
small
modest
impact
antimicrobi
escal
signific
percentag
patient
modif
therapi
lrp
use
given
sampl
still
requir
tradit
cultur
laboratori
workflow
budget
impact
concern
incorpor
lrp
workflow
like
affect
abil
assay
impact
patient
care
tabl
provid
critic
question
address
lrp
adopt
given
challeng
limit
lrp
like
complet
replac
tradit
cultur
therefor
supplement
method
limit
add
cost
workup
diagnosi
lrt
infect
like
signific
impact
laboratori
budget
workflow
howev
abil
significantli
impact
antibiot
use
modifi
provid
appropri
therapi
earli
diseas
cours
occur
could
dramat
improv
patient
outcom
format
diagnost
stewardship
team
includ
clinic
microbiolog
antibiot
stewardship
pharmacist
infect
control
practition
infecti
diseas
physician
benefici
establish
institut
practic
guidelin
lrp
implement
therebi
ensur
prudent
appropri
use
lrp
larger
multicent
outcom
studi
need
fulli
assess
impact
lrp
patient
care
hospit
cost
determin
advantag
lrp
justifi
cost
laboratori
perform
specimen
qualiti
assess
via
gram
stain
specimen
assess
criteria
need
modifi
lrp
use
test
perform
firsttim
specimen
repeat
specimen
enter
li
phone
primari
physician
phone
diagnost
antibiot
stewardship
result
treat
critic
valu
result
incorpor
final
cultur
result
test
biomark
ie
creactiv
protein
procalcitonin
perform
conjunct
lrp
